{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T17:29:10Z","timestamp":1792517350405,"version":"4.5.0"},"reference-count":98,"publisher":"Springer Science and Business Media LLC","issue":"23-24","license":[{"start":{"date-parts":[[2010,12,1]],"date-time":"2010-12-01T00:00:00Z","timestamp":1291161600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Wien Med Wochenschr"],"published-print":{"date-parts":[[2010,12]]},"DOI":"10.1007\/s10354-010-0841-y","type":"journal-article","created":{"date-parts":[[2011,1,7]],"date-time":"2011-01-07T07:47:42Z","timestamp":1294386462000},"page":"609-624","source":"Crossref","is-referenced-by-count":88,"title":["An overview on bone manifestations in Gaucher disease","Eine \u00dcbersicht zu Knochenmanifestationen bei Morbus Gaucher"],"prefix":"10.1007","volume":"160","author":[{"given":"Peter","family":"Mikosch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derralynn","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"841_CR1","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.ejim.2006.07.005","volume":"17","author":"A Mehta","year":"2006","unstructured":"Mehta A. Epidemiology and natural history of Gaucher's disease. Eur J Intern Med, 17: S2\u2013S5, 2006","journal-title":"Eur J Intern Med"},{"key":"841_CR2","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.0009-9163.2004.00217.x","volume":"65","author":"DP Germain","year":"2004","unstructured":"Germain DP. Gaucher's disease: a paradigm for interventional genetics. Clin Genet, 65: 77\u201386, 2004","journal-title":"Clin Genet"},{"key":"841_CR3","unstructured":"Walton-Bowen K, Mantick N. Gaucher Registry Annual Aggregate Data Report. 2000"},{"key":"841_CR4","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.3324\/haematol.12651","volume":"93","author":"M de Fost","year":"2008","unstructured":"de Fost M, van Noesel CJM, Aerts JM, et al. Persistent bone disease in adult type 1 Gaucher disease despite increasing doses of enzyme replacement therapy. Haematologica, 93: 1119\u20131120, 2008","journal-title":"Haematologica"},{"key":"841_CR5","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1093\/qjmed\/90.1.19","volume":"90","author":"MJ Allen","year":"1997","unstructured":"Allen MJ, Meyer BJ, Khokher AM, et al. Pro-inflammatory cytokines and the pathogenesis of Gaucher's disease: increased release of interleukin-6 and interleukin-10. QJM, 90: 19\u201325, 1997","journal-title":"QJM"},{"key":"841_CR6","first-page":"205","volume":"10","author":"V Barak","year":"1999","unstructured":"Barak V, Acker M, Nisman B, et al. Cytokines in Gaucher's disease. Eur Cytokine Netw, 10: 205\u2013210, 1999","journal-title":"Eur Cytokine Netw"},{"key":"841_CR7","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1006\/bcmd.1997.0137","volume":"23","author":"CE Hollak","year":"1997","unstructured":"Hollak CE, Evers L, Aerts JM, et al. Elevated levels of M-CSF, sCD14 and IL8 in type 1 Gaucher disease. Blood Cells Mol Dis, 23: 201\u2013212, 1997","journal-title":"Blood Cells Mol Dis"},{"key":"841_CR8","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1111\/j.1442-200X.2007.02502.x","volume":"49","author":"M Yoshino","year":"2007","unstructured":"Yoshino M, Watanabe Y, Tokunaga Y, et al. Roles of specific cytokines in bone remodelling and hematopoisis in Gaucher disease. Pediatr Int, 49: 959\u2013965, 2007","journal-title":"Pediatr Int"},{"key":"841_CR9","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1006\/bcmd.1997.0156","volume":"23","author":"M Lichtenstein","year":"1997","unstructured":"Lichtenstein M, Zimran A, Horowitz M. Cytokine mRNA in Gaucher disease. Blood Cells Mol Dis, 23: 395\u2013401, 1997","journal-title":"Blood Cells Mol Dis"},{"key":"841_CR10","doi-asserted-by":"crossref","first-page":"3134","DOI":"10.1182\/blood-2009-07-233601","volume":"114","author":"PM Campeau","year":"2009","unstructured":"Campeau PM, Rafei M, Boivin MN, et al. Characterization of Gaucher disease bone marrow mesenchymal stromal cells reveals an altered inflammatory secretome. Blood, 114: 3134\u20133135, 2009","journal-title":"Blood"},{"key":"841_CR11","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1182\/blood.V100.6.2195","volume":"100","author":"M Abe","year":"2002","unstructured":"Abe M, Hiura K, Wilde J, et al. Role for macrophage inflammatory protein (MIP)-1\u03b1 and MIP-1\u03b2 in the development of osteolytic in multiple myeloma. Blood, 100: 2195\u20132302, 2002","journal-title":"Blood"},{"key":"841_CR12","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.bbadis.2007.04.002","volume":"1772","author":"MJ Breemen","year":"2007","unstructured":"Breemen MJ, de Fost M, Voerman JS, et al. Increased plasma macrophage inflammatory protein (MIP)-1alpha and MIP-1beta levels in type 1 Gaucher disease. Biochim Biophys Acta, 1772: 788\u2013796, 2007","journal-title":"Biochim Biophys Acta"},{"key":"841_CR13","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1006\/bcmd.1999.0237","volume":"25","author":"L Lacerda","year":"1999","unstructured":"Lacerda L, Arosa FA, Lacerda R, et al. T cell numbers relate to bone involvement in Gaucher disease. Blood Cells Mol Dis, 25: 130\u2013138, 1999","journal-title":"Blood Cells Mol Dis"},{"key":"841_CR14","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1007\/s10354-009-0647-y","volume":"159","author":"W Sipos","year":"2009","unstructured":"Sipos W, Pietschmann P, Rauner M, et al. Pathophysiology of osteoporosis. Wiener Med Wochenschr, 159: 230\u2013234, 2009","journal-title":"Wiener Med Wochenschr"},{"key":"841_CR15","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.bcmd.2009.08.002","volume":"43","author":"S Piran","year":"2009","unstructured":"Piran S, Roberts A, Patterson MA, et al. The clinical course of untreated Gaucher disease in 22 patients over 10 years: haematological and skeletal manifestations. Blood Cells Mol Dis, 43: 289\u2013293, 2009","journal-title":"Blood Cells Mol Dis"},{"key":"841_CR16","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s11136-004-0794-y","volume":"14","author":"P Giraldo","year":"2005","unstructured":"Giraldo P, Salano V, Perez-Calvo JI, et al. Spanish Group on Gaucher Disease. Quality of life to type 1 Gaucher disease: Spanish experience. Qual Life Res, 14: 453\u2013462, 2005","journal-title":"Qual Life Res"},{"issue":"Suppl 1","key":"841_CR17","doi-asserted-by":"crossref","first-page":"A2","DOI":"10.1259\/bjr.75.suppl_1.750002","volume":"75","author":"RJ Wenstrup","year":"2002","unstructured":"Wenstrup RJ, Roca-Espiau M, Weinreb NJ, et al. Skeletal aspects of Gaucher disease: a review. Br J Radiol, 75(Suppl 1): A2\u2013A12, 2002","journal-title":"Br J Radiol"},{"issue":"Suppl 1","key":"841_CR18","doi-asserted-by":"crossref","first-page":"A37","DOI":"10.1259\/bjr.75.suppl_1.750037","volume":"75","author":"B Bembi","year":"2002","unstructured":"Bembi B, Ciana G, Mengel E, et al. Bone complications in children with Gaucher disease. Br J Radiol, 75(Suppl 1): A37\u2013A44, 2002","journal-title":"Br J Radiol"},{"key":"841_CR19","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s10545-007-0621-z","volume":"30","author":"PG Sido","year":"2007","unstructured":"Sido PG, Drugan C, Cret V, et al. Outcome of enzyme replacement therapy in patients with Gaucher disease type I. The Romanian experience. J Inherit Metab Dis, 30: 783\u2013789, 2007","journal-title":"J Inherit Metab Dis"},{"key":"841_CR20","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1002\/ajmg.a.32253","volume":"149A","author":"MA Faden","year":"2009","unstructured":"Faden MA, Krakow D, Ezgu F, et al. The Erlenmeyer flask bone deformity in the skeletal dysplasias. Am J Med Gen A, 149A: 1334\u20131345, 2009","journal-title":"Am J Med Gen A"},{"key":"841_CR21","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1002\/jbmr.5650111125","volume":"11","author":"G Pastores","year":"1996","unstructured":"Pastores G, Wallenstein S, Desnick RJ, et al. Bone density in type 1 Gaucher disease. J Bone Min Res, 11: 1801\u20131807, 1996","journal-title":"J Bone Min Res"},{"key":"841_CR22","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1182\/blood.V96.5.1969","volume":"96","author":"MT Moran","year":"2000","unstructured":"Moran MT, Schofield JP, Hayman AR, et al. Pathologic gene expresion in Gaucher disease: up-regulation of cysteine proteinases including osteoclastic cathepsin K. Blood, 96: 1969\u20131978, 2000","journal-title":"Blood"},{"key":"841_CR23","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/BF00269916","volume":"8","author":"M Watanabe","year":"1984","unstructured":"Watanabe M, Yanagisawa M, Sonobe S, et al. An adult form of Gaucher's disease with a huge tumour formation of the right tibia. Int Orthop, 8: 195\u2013202, 1984","journal-title":"Int Orthop"},{"key":"841_CR24","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S0720-048X(97)01158-3","volume":"26","author":"H Ozturk","year":"1998","unstructured":"Ozturk H, Unsal M, Aydingoz U, et al. Pseudotumor formation in tibia in Gaucher's disease. Eur J Radiol, 26: 284\u2013286, 1998","journal-title":"Eur J Radiol"},{"key":"841_CR25","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/BF02412357","volume":"23","author":"G Hermann","year":"1994","unstructured":"Hermann G, Shapiro R, Abdelwahab F, et al. Extraosseous extension of Gaucher cell deposits mimicking malignancy. Skelet Radiol, 23: 253\u2013256, 1994","journal-title":"Skelet Radiol"},{"key":"841_CR26","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s002560050003","volume":"29","author":"LW Poll","year":"2000","unstructured":"Poll LW, Koch JA, vom Dahl S, et al. Type I Gaucher disease: extraosseous extension of skeletal disease. Skeletal Radiol, 29: 15\u201321, 2000","journal-title":"Skeletal Radiol"},{"key":"841_CR27","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1007\/s003300000446","volume":"10","author":"LW Poll","year":"2000","unstructured":"Poll LW, Koch JA, vom Dahl S, et al. Extraosseous manifestation of Gaucher's disease type I: MR and histological appearance. Eur Radiol, 10: 1660\u20131663, 2000","journal-title":"Eur Radiol"},{"key":"841_CR28","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1097\/00005792-198509000-00003","volume":"64","author":"DW Stowens","year":"1985","unstructured":"Stowens DW, Teitelbaum SL, Kahn AJ, et al. Skeletal complications of Gaucher disease. Medicine, 64: 310\u2013322, 1985","journal-title":"Medicine"},{"key":"841_CR29","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1006\/bcmd.2001.0479","volume":"28","author":"C Drugan","year":"2002","unstructured":"Drugan C, Jebeleanu G, Grigorescu-Sido P, et al. Biochemical markers of bone turnover as tools in the evaluation of skeletal involvement in patients with type 1 Gaucher disease. Blood Cells Mol Dis, 28: 13\u201320, 2002","journal-title":"Blood Cells Mol Dis"},{"key":"841_CR30","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s00223-001-2072-0","volume":"72","author":"G Ciana","year":"2003","unstructured":"Ciana G, Martini C, Leopaldi A, et al. Bone marker alterations in patients with type 1 Gaucher disease. Calcif Tissue Int, 72: 185\u2013189, 2003","journal-title":"Calcif Tissue Int"},{"key":"841_CR31","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s10545-005-0032-y","volume":"28","author":"G Ciana","year":"2005","unstructured":"Ciana G, Addobbati R, Tamaro G, et al. Gaucher disease and bone: laboratory and skeletal mineral density variations during a long period of enzyme replacement therapy. J Inherit Metab Dis, 28: 723\u2013732, 2005","journal-title":"J Inherit Metab Dis"},{"key":"841_CR32","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1111\/j.1399-0004.2008.00978.x","volume":"73","author":"KB Sims","year":"2008","unstructured":"Sims KB, Pastores GM, Weinreb NJ, et al. Improvement of bone disease by imiglucerase (Cerecyme) therapy in patients with skeletal manifestations of type 1 Gaucher disease: results of a 48-month longitudinal cohort study. Clin Genet, 73: 430\u2013440, 2008","journal-title":"Clin Genet"},{"key":"841_CR33","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1006\/bcmd.2002.0517","volume":"28","author":"R Schiffmann","year":"2002","unstructured":"Schiffmann R, Mankin H, Dambrosia JM, et al. Decreased bone density in splenectomized Gaucher patients receiving enzyme replacement therapy. Blood Cells Mol Dis, 28: 288\u2013296, 2002","journal-title":"Blood Cells Mol Dis"},{"key":"841_CR34","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s774-002-8444-1","volume":"20","author":"CE Fiore","year":"2002","unstructured":"Fiore CE, Barone R, Pennisi P, et al. Bone ultrasonometry, bone density, and bone turnover markers in type 1 Gaucher disease. J Bone Miner Metab, 20: 24\u201338, 2002","journal-title":"J Bone Miner Metab"},{"key":"841_CR35","first-page":"31","volume":"13","author":"MS Parisi","year":"2008","unstructured":"Parisi MS, Mastaglia SR, Bagur A, et al. Body composition and bone metabolism in young Gaucher disease type I patients treated with imiglucerase. Eur J Med Res, 13: 31\u201338, 2008","journal-title":"Eur J Med Res"},{"key":"841_CR36","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s00223-008-9143-4","volume":"83","author":"P Mikosch","year":"2008","unstructured":"Mikosch P, Reed M, Baker R, et al. Changes of bone metabolism in seven patients with Gaucher disease treated consecutively with imiglucerase and miglustat. Calcif Tissue Int, 83: 43\u201354, 2008","journal-title":"Calcif Tissue Int"},{"key":"841_CR37","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/j.1365-2141.2006.05978.x","volume":"133","author":"I Magal","year":"2006","unstructured":"Magal I, Lebel E, Altarescu G, et al. Serum levels of osteoprotegerin and osteoprotegerin polymorphisms in Gaucher disease. Br J Haematol, 133: 93\u201397, 2006","journal-title":"Br J Haematol"},{"key":"841_CR38","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ymgme.2008.12.001","volume":"96","author":"P Mikosch","year":"2009","unstructured":"Mikosch P, Reed M, Stettner H, et al. Patients with Gaucher disease living in England show a high prevalence of vitamin D insufficiency with correlation to osteodensitometry. Mol Genet, 96: 113\u2013120, 2009","journal-title":"Mol Genet"},{"key":"841_CR39","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1185\/030079906X104623","volume":"22","author":"S Vom Dahl","year":"2006","unstructured":"Vom Dahl S, Poll L, Di Rocco M, et al. Evidence-based recommendations for monitoring bone disease and the response to enzyme replacement therapy in Gaucher patients. Curr Med Res Opin, 22: 1045\u20131064, 2006","journal-title":"Curr Med Res Opin"},{"issue":"Suppl 1","key":"841_CR40","doi-asserted-by":"crossref","first-page":"A13","DOI":"10.1259\/bjr.75.suppl_1.750013","volume":"75","author":"M Maas","year":"2002","unstructured":"Maas M, Poll LW, Terk MR. Imaging and quantifying skeletal involvement in Gaucher disease. Br J Radiol, 75(Suppl 1): A13\u2013A24, 2002","journal-title":"Br J Radiol"},{"key":"841_CR41","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1006\/bcmd.2001.0474","volume":"27","author":"C Hollak","year":"2001","unstructured":"Hollak C, Maas M, Akkerman E, et al. Dixon quantitative chemical shift imaging is a sensitive tool for the evaluation of bone marrow responses to individualized doses of enzyme supplementation therapy in type 1 Gaucher disease. Blood Cells Mol Dis, 27: 1005\u20131012, 2001","journal-title":"Blood Cells Mol Dis"},{"key":"841_CR42","doi-asserted-by":"crossref","first-page":"961","DOI":"10.2214\/ajr.179.4.1790961","volume":"179","author":"M Maas","year":"2002","unstructured":"Maas M, Hollak CE, Akkermann EM, et al. Quantification of skeletal involvement in adults with type 1 Gaucher's disease: fat fraction measured by Dixon quantitative chemical shift imaging as a valid parameter. Am J Roentgenol, 179: 961\u2013965, 2002","journal-title":"Am J Roentgenol"},{"key":"841_CR43","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1148\/radiol.2292020296","volume":"229","author":"M Maas","year":"2003","unstructured":"Maas M, van Kuijk C, Stoker J, et al. Quantification of bone involvement in Gaucher disease: MR imaging bone marrow burden score as an alternative to Dixon quantitative chemical shift MR imaging \u2013 initial experience. Radiology, 229: 554\u2013561, 2003","journal-title":"Radiology"},{"key":"841_CR44","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ejrad.2006.11.024","volume":"52","author":"M Roca","year":"2007","unstructured":"Roca M, Mota J, Alfonso P, et al. S-MRI score: a simple method for assessing bone marrow involvement in Gaucher disease. Eur J Radiol, 52: 132\u2013137, 2007","journal-title":"Eur J Radiol"},{"key":"841_CR45","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1097\/00004728-200209000-00031","volume":"26","author":"EJ Vlieger","year":"2002","unstructured":"Vlieger EJ, Maas M, Akkerman EM, et al. Vertebral disc ration as a parameter for bone marrow involvement. J Comput Assit Tomogr, 26: 843\u2013848, 2002","journal-title":"J Comput Assit Tomogr"},{"key":"841_CR46","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1007\/s002560100375","volume":"30","author":"LW Poll","year":"2001","unstructured":"Poll LW, Koch JA, vom Dahl S, et al. Magnetic resonance imaging of bone marrow changes in Gaucher disease during enzyme replacement therapy: first German long-term results. Skelet Radiol, 30: 496\u2013503, 2001","journal-title":"Skelet Radiol"},{"issue":"Suppl 1","key":"841_CR47","doi-asserted-by":"crossref","first-page":"A25","DOI":"10.1259\/bjr.75.suppl_1.750025","volume":"75","author":"LW Poll","year":"2002","unstructured":"Poll LW, Maas M, Terk MR, et al. Response of Gaucher bone disease to enzyme replacement therapy. Br J Radiol, 75(Suppl 1): A25\u2013A36, 2002","journal-title":"Br J Radiol"},{"key":"841_CR48","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.2214\/AJR.06.1410","volume":"188","author":"PL Robertson","year":"2007","unstructured":"Robertson PL, Maas M, Goldblatt J. Semiquantitive assessment of skeletal response to enzyme replacement therapy for Gaucher's disease using the bone marrow burden score. Am J Roentgenol, 188: 1521\u20131528, 2007","journal-title":"Am J Roentgenol"},{"key":"841_CR49","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.3324\/haematol.2009.008078","volume":"94","author":"P Giraldo","year":"2009","unstructured":"Giraldo P, Alfonso P, Atutxa K, et al. Real-world clinical experience with long term miglustat maintenance therapy in type 1 Gaucher disease: the ZAGAL project. Haematologica, 94: 1771\u20131775, 2009","journal-title":"Haematologica"},{"key":"841_CR50","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s00256-007-0425-0","volume":"37","author":"M Mass","year":"2008","unstructured":"Mass M, Hangartner T, Mariani G, et al. Recommendations for the assessment and monitoring of skeletal manifestations in children with Gaucher disease. Skelet Radiol, 37: 185\u2013188, 2008","journal-title":"Skelet Radiol"},{"key":"841_CR51","doi-asserted-by":"crossref","first-page":"239","DOI":"10.3413\/nukmed-0142","volume":"47","author":"P Mikosch","year":"2008","unstructured":"Mikosch P, Kohlf\u00fcrst S, Gallowitsch HJ, et al. Is there a role for scintigraphic imaging of bone manifestations in Gaucher disease? Nuklearmedizin, 47: 239\u2013247, 2008","journal-title":"Nuklearmedizin"},{"key":"841_CR52","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/00003072-199204000-00003","volume":"17","author":"TR Bilchik","year":"1992","unstructured":"Bilchik TR, Heyman S. Skeletal scintigraphy of pseudo-osteomyelitis in Gaucher's disease. Two case reports and a review of the literature. Clin Nucl Med, 17: 279\u2013282, 1992","journal-title":"Clin Nucl Med"},{"key":"841_CR53","first-page":"1253","volume":"44","author":"G Mariani","year":"2003","unstructured":"Mariani G, Filocamo M, Giona F, et al. Severity of bone marrow involvement in patients with Gaucher's disease evaluated by scintigraphy with 99mTc-sestamibi. J Nucl Med, 44: 1253\u20131262, 2003","journal-title":"J Nucl Med"},{"key":"841_CR54","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1007\/BF01247378","volume":"23","author":"G Mariani","year":"1996","unstructured":"Mariani G, Molea N, La Civita L, et al. Scintigraphic findings on 99mTc-MDP, 99mTc-sestamibi and 99mTc-HMPAO images in Gaucher's disease. Eur J Nucl Med, 23: 466\u2013470, 1996","journal-title":"Eur J Nucl Med"},{"key":"841_CR55","first-page":"283","volume-title":"Gaucher disease","author":"G Mariani","year":"2007","unstructured":"Mariani G, Erba PA. Radionuclide evaluation of Gaucher disease. In: Futerman T, Zimran A (eds) Gaucher disease. CRC Press, Boca Raton, FL, 2007, pp 283\u2013315"},{"key":"841_CR56","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1034\/j.1600-0609.2003.00047.x","volume":"70","author":"Z Rudzki","year":"2003","unstructured":"Rudzki Z, Oko\u0144 K, Machaczka M, et al. Enzyme replacement therapy reduces Gaucher cell burden but may accelerate osteopenia in patients with type I disease \u2013 histological study. Eur J Haematol, 70: 273\u2013281, 2003","journal-title":"Eur J Haematol"},{"key":"841_CR57","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1359\/jbmr.061004","volume":"21","author":"RJ Wenstrup","year":"2007","unstructured":"Wenstrup RJ, Kacena KA, Kaplan P, et al. Effect of enzyme replacement therapy with imiglucerase on BMD in type 1 Gaucher disease. J Bone Miner Res, 21: 119\u2013126, 2007","journal-title":"J Bone Miner Res"},{"issue":"Suppl 5","key":"841_CR58","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1053\/j.seminhematol.2004.07.010","volume":"41","author":"NJ Weinreb","year":"2004","unstructured":"Weinreb NJ, Aggio MC, Andersson HC, et al. International Collaborative Gaucher Group (ICGG). Gaucher disease type 1: revised recommendations on evaluations and monitoring for adult patients. Semin Hematol, 41(Suppl 5): 15\u201322, 2004","journal-title":"Semin Hematol"},{"key":"841_CR59","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1001\/archinte.158.16.1754","volume":"158","author":"J Charrow","year":"1998","unstructured":"Charrow J, Esplin JA, Gribble TJ, et al. Gaucher disease \u2013 recommendations on diagnosis, evaluation and monitoring. Arch Intern Med, 158: 1754\u20131760, 1998","journal-title":"Arch Intern Med"},{"key":"841_CR60","unstructured":"Beck M, vom Dahl S, Mengel E, et al. Leitlinie zu Morbus Gaucher. Arbeitsgemeinschaft f\u00fcr P\u00e4diatrische Speichererkrankungen in der Deutschen Gesellschaft f\u00fcr Kinder- und Jugendmedizin ( www.aps-med.de )"},{"key":"841_CR61","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1385\/JCD:8:4:371","volume":"8","author":"S Baim","year":"2005","unstructured":"Baim S, Wilson CR, Lewiecki EM, et al. Precision assessment and radiation safety for dual-energy X-ray absorptiometry: position paper of the International Society for Clinical Densitometry. J Clin Densitom, 8: 371\u2013378, 2005","journal-title":"J Clin Densitom"},{"key":"841_CR62","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1385\/JCD:6:2:97","volume":"6","author":"SL Morgan","year":"2003","unstructured":"Morgan SL, Abercrombie W, Lee JY. Need for precision studies at individual institutions and assessment of size of regions of interest on serial DXA scans. J Clin Densitom, 6: 97\u2013101, 2003","journal-title":"J Clin Densitom"},{"key":"841_CR63","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s10354-009-0657-9","volume":"159","author":"DP Dimai","year":"2009","unstructured":"Dimai DP. Diagnostik der Osteoporose. Wien Med Wochenschr, 159: 241\u2013246, 2009","journal-title":"Wien Med Wochenschr"},{"key":"841_CR64","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1136\/bmj.327.7413.462","volume":"327","author":"AB Mehta","year":"2003","unstructured":"Mehta AB, Lewis S, Laverey C. Treatment of lysosomal storage disorders. BMJ, 327: 462\u2013463, 2003","journal-title":"BMJ"},{"key":"841_CR65","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1053\/j.seminhematol.2004.07.009","volume":"41","author":"GM Pastores","year":"2004","unstructured":"Pastores GM, Weinreb NJ, Aerts H, et al. Therapeutic goals in the treatment of Gaucher disease. Semin Hematol, 41: 4\u201314, 2004","journal-title":"Semin Hematol"},{"key":"841_CR66","doi-asserted-by":"crossref","first-page":"33","DOI":"10.7326\/0003-4819-122-1-199501010-00005","volume":"122","author":"GA Grabowski","year":"1995","unstructured":"Grabowski GA, Barton NW, Pastores G, et al. Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant resources. Ann Intern Med, 122: 33\u201339, 1995","journal-title":"Ann Intern Med"},{"key":"841_CR67","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1093\/qjmed\/91.7.483","volume":"91","author":"D Elstein","year":"1998","unstructured":"Elstein D, Abrahamov A, Hadas-Halpern I, et al. Low-dose low-frequency imiglucerase as a starting regimen of enzyme replacement therapy for patients with type I Gaucher disease. QJM, 91: 483\u2013488, 1998","journal-title":"QJM"},{"key":"841_CR68","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1016\/S0140-6736(95)91037-9","volume":"345","author":"CE Hollak","year":"1995","unstructured":"Hollak CE, Aerts JM, Goudsmit R, et al. Individualised low-dose alglucerase therapy for type 1 Gaucher disease. Lancet, 345: 1474\u20131478, 1995","journal-title":"Lancet"},{"key":"841_CR69","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1182\/blood.V82.2.408.408","volume":"82","author":"GM Pastores","year":"1993","unstructured":"Pastores GM, Sibille AR, Grabowski GA. Enzyme therapy in Gaucher disease type 1: dosage efficacy and adverse effects in 33 patients treated for 6 to 24 months. Blood, 82: 408\u2013416, 1993","journal-title":"Blood"},{"key":"841_CR70","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1182\/blood-2005-12-5072","volume":"108","author":"M de Fost","year":"2006","unstructured":"de Fost M, Hollak CE, Groener JE, et al. Superior effects of high-dose enzyme replacement therapy in type 1 Gaucher disease on bone marrow involvement and chitotriosidase levels: a 2-center retrospective analysis. Blood, 108: 850\u2013855, 2006","journal-title":"Blood"},{"key":"841_CR71","first-page":"749","volume":"144","author":"J T\u00f3th","year":"2003","unstructured":"T\u00f3th J, Sz\u00fccs FZ, Benk\u00f6 K, et al. Enzyme replacement therapy in Gaucher disease: monitoring visceral and bone changes with MRI. Orv Hetil, 144: 749\u2013755, 2003","journal-title":"Orv Hetil"},{"key":"841_CR72","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/j.1399-0004.2007.00769.x","volume":"71","author":"J Charrow","year":"2007","unstructured":"Charrow J, Dulisse B, Grabowski GA, et al. The effect of enzyme replacement therapy on bone crisis and bone pain in patients with type 1 Gaucher disease. Clin Genet, 71: 205\u2013211, 2007","journal-title":"Clin Genet"},{"key":"841_CR73","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S0002-9343(02)01150-6","volume":"113","author":"NJ Weinreb","year":"2002","unstructured":"Weinreb NJ, Charrow J, Andersson HC, et al. Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry. Am J Med, 113: 112\u2013119, 2002","journal-title":"Am J Med"},{"key":"841_CR74","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1111\/j.1399-0004.2007.00811.x","volume":"71","author":"N Weinreb","year":"2007","unstructured":"Weinreb N, Barranger J, Packman S, et al. Imiglucerase (Cerezyme) improves quality of life in patients with skeletal manifestations of Gaucher disease. Clin Genet, 71: 576\u2013588, 2007","journal-title":"Clin Genet"},{"key":"841_CR75","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/s00774-004-0529-8","volume":"22","author":"E Lebel","year":"2004","unstructured":"Lebel E, Dweck A, Foldes AJ, et al. Bone density changes with enzyme therapy in Gaucher disease. J Bone Miner Metab, 22: 597\u2013601, 2004","journal-title":"J Bone Miner Metab"},{"key":"841_CR76","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1016\/S0140-6736(94)90462-6","volume":"344","author":"B Bembi","year":"1994","unstructured":"Bembi B, Zanatta M, Carrozzi M, et al. Enzyme replacement treatment in type 1 and type 3 Gaucher's disease. Lancet, 344: 1679\u20131682, 1994","journal-title":"Lancet"},{"key":"841_CR77","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1542\/peds.2007-2144","volume":"122","author":"H Andersson","year":"2008","unstructured":"Andersson H, Kaplan P, Kacena K, Yee J. Eight-year outcomes of long-term enzyme replacement therapy for 884 children with Gaucher disease type 1. Pediatrics, 122: 1182\u20131190, 2008","journal-title":"Pediatrics"},{"key":"841_CR78","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.jpeds.2007.02.057","volume":"151","author":"G Drelichman","year":"2007","unstructured":"Drelichman G, Ponce E, Basack N, et al. Clinical concequences of interrupting enzyme replacement therapy in children with type 1 Gaucher disease. J Pediatr, 151: 197\u2013201, 2007","journal-title":"J Pediatr"},{"key":"841_CR79","first-page":"703","volume":"91","author":"P Giraldo","year":"2006","unstructured":"Giraldo P, Latre P, Alfonso P, et al. Short-term effect of miglustat in every day clinical use in treatment-naive or previously treated patients with type 1 Gaucher's disease. Haematologica, 91: 703\u2013706, 2006","journal-title":"Haematologica"},{"key":"841_CR80","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1023\/B:BOLI.0000045756.54006.17","volume":"27","author":"D Elstein","year":"2004","unstructured":"Elstein D, Hollak C, Aerts JM, et al. Sustained therapeutic effects of oral miglustat (Zavesca, N-butyldeoxynojirimycin, OGT 918) in type I Gaucher disease. J Inherit Metab Dis, 27: 757\u2013766, 2004","journal-title":"J Inherit Metab Dis"},{"key":"841_CR81","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.clinthera.2005.08.004","volume":"27","author":"GM Pastores","year":"2005","unstructured":"Pastores GM, Barnett NL, Kolodny EH. An open-label, non-comparative study of miglustat in type I Gaucher disease: efficacy and tolerability over 24 months of treatment. Clin Ther, 27: 1215\u20131227, 2005","journal-title":"Clin Ther"},{"key":"841_CR82","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1016\/j.clinthera.2007.08.006","volume":"29","author":"G Pastores","year":"2007","unstructured":"Pastores G, Elstein D, Hrebicek M, et al. Effect of miglustat on bone disease in adults with type 1 Gaucher disease: a pooled analysis of three multinational open-label studies. Clin Ther, 29: 1645\u20131654, 2007","journal-title":"Clin Ther"},{"key":"841_CR83","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1254\/jphs.FMJ05004X3","volume":"100","author":"S Fukomoto","year":"2006","unstructured":"Fukomoto S, Iwamoto T, Sakai E, et al. Current topics in pharmacological research on bone metabolism: osteoclast differentiation regulated by glycoshingolipids. J Pharmacol Sci, 100: 195\u2013200, 2006","journal-title":"J Pharmacol Sci"},{"key":"841_CR84","doi-asserted-by":"crossref","unstructured":"Peterschmitt J, Lukina E, Watman NP, et al. Genz-112638 for Gaucher Disease Type 1: Phase 2 Clinical Trial Results After 18 Months of Treatment. 51st ASH Annual Meeting and Exposition, New Orleans, December 2009, Abstract 1349","DOI":"10.1182\/blood.V114.22.1349.1349"},{"key":"841_CR85","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1182\/blood-2003-11-3854","volume":"104","author":"RJ Wenstrup","year":"2004","unstructured":"Wenstrup RJ, Bailey L, Grabowski GA, et al. Gaucher disease: alendronate disodium improves bone mineral density in adults receiving enzyme therapy. Blood, 104: 1253\u20131257, 2004","journal-title":"Blood"},{"key":"841_CR86","first-page":"1391","volume":"35","author":"AA Khan","year":"2008","unstructured":"Khan AA, Sa\u0144dor GK, Dore E, et al. Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw. J Rheumatol, 35: 1391\u20131397, 2008","journal-title":"J Rheumatol"},{"key":"841_CR87","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s00066-010-2066-9","volume":"186","author":"V Vassiliou","year":"2010","unstructured":"Vassiliou V, Tselis N, Kardamakis D. Osteonecrosis of the jaws: clinicopathologic and radiologic characteristics, preventive and therapeutic strategies. Strahlenther Onkol, 186: 367\u2013373, 2010","journal-title":"Strahlenther Onkol"},{"key":"841_CR88","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1016\/j.clinthera.2007.08.008","volume":"29","author":"M Pazianas","year":"2007","unstructured":"Pazianas M, Miller P, Blumentals WA, et al. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics. Clin Ther, 29: 1548\u20131558, 2007","journal-title":"Clin Ther"},{"key":"841_CR89","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.joms.2009.09.037","volume":"68","author":"A Goss","year":"2010","unstructured":"Goss A, Bartold M, Sambrook P, et al. The nature and frequncy of bisphosphonate-associated osteonecrosis of the jaws in dental implant patients: a South Australian case series. J Oral Maxillofac Surg, 68: 337\u2013343, 2010","journal-title":"J Oral Maxillofac Surg"},{"key":"841_CR90","unstructured":"Wilde F, Heufelder M, Winter K, et al. The role of surgical therapy in the management of intravenous bisphosphonates-related osteonecrosis of the jaw. Oral Surg Oral Med oral Pathol Oral Radiol Endod, 2010 July 31 (Epub ahead of print)"},{"key":"841_CR91","first-page":"37","volume":"65","author":"KF Lutsky","year":"2007","unstructured":"Lutsky KF, Tejwani NC. Orthopaedic manifestations of Gaucher disease. Bull NYU Hosp Jt Dis, 65: 37\u201342, 2007","journal-title":"Bull NYU Hosp Jt Dis"},{"key":"841_CR92","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1016\/j.lpm.2007.04.012","volume":"36","author":"RM Javier","year":"2007","unstructured":"Javier RM, Hachulla E. Osteoarticular manifestations of Gaucher disease in adults: pathophysiology and treatment. Presse Med, 36: 1971\u20131984, 2007","journal-title":"Presse Med"},{"key":"841_CR93","doi-asserted-by":"crossref","first-page":"201","DOI":"10.3109\/17453670902930032","volume":"80","author":"E Lebel","year":"2009","unstructured":"Lebel E, Phillips M, Elstein D, et al. Poor results of drilling in early stages of juxta-articular osteonecrosis in 12 joints affected by Gaucher disease. Acta Orthop, 80: 201\u2013204, 2009","journal-title":"Acta Orthop"},{"key":"841_CR94","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1177\/145749690309200309","volume":"92","author":"P Mattsson","year":"2003","unstructured":"Mattsson P, Larsson S. Stability of internally fixed femoral neck fractures augmented with resorbable cement. A prospective randomized study using radiostereometry. Scand J Surg, 92: 215\u2013219, 2003","journal-title":"Scand J Surg"},{"key":"841_CR95","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1097\/BLO.0b013e3180373138","volume":"459","author":"WH Rijnen","year":"2007","unstructured":"Rijnen WH, Gardeniers JW, Schreurs BW, et al. Impacted bone and calcium phosphate cement for repair of femoral head defects: a pilot study. Clin Orthop Relat Res, 459: 216\u2013221, 2007","journal-title":"Clin Orthop Relat Res"},{"key":"841_CR96","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.mehy.2009.10.039","volume":"74","author":"VY Ng","year":"2010","unstructured":"Ng VY, Granger JF, Ellis TJ. Calcium phosphate cement to prevent collapse in avascular necrosis of the femoral head. Med Hypotheses, 74: 725\u2013726, 2010","journal-title":"Med Hypotheses"},{"key":"841_CR97","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2214\/AJR.07.3550","volume":"191","author":"RF DeMayo","year":"2008","unstructured":"DeMayo RF, Haims AH, McRae MC, et al. Correlation of MRI-based bone marrow burden score with genotype and spleen status in Gaucher's disease. AJR, 191: 115\u2013123, 2008","journal-title":"AJR"},{"key":"841_CR98","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1023\/A:1005451300167","volume":"22","author":"H Ida","year":"1999","unstructured":"Ida H, Rennert OM, Kato S, et al. Severe skeletal complications in Japanese patients with type 1 Gaucher disease. J Inherit Metab Dis, 22: 63\u201373, 1999","journal-title":"J Inherit Metab Dis"}],"container-title":["Wiener Medizinische Wochenschrift"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10354-010-0841-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10354-010-0841-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10354-010-0841-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,2]],"date-time":"2024-04-02T20:25:15Z","timestamp":1712089515000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10354-010-0841-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,12]]},"references-count":98,"journal-issue":{"issue":"23-24","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["841"],"URL":"https:\/\/doi.org\/10.1007\/s10354-010-0841-y","relation":{},"ISSN":["0043-5341","1563-258X"],"issn-type":[{"value":"0043-5341","type":"print"},{"value":"1563-258X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,12]]}}}